Vigonvita Life Sciences Co Ltd
02630
Company Profile
Business description
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is engaged in the discovery, acquisition, development, and commercialization of small-molecule drugs in strategically focused therapeutic areas, namely neuropsychiatry, reproductive health, and viral infection. The company's core Products include LV232, for the treatment of depressive disorder, and TPN171, for the treatment of erectile dysfunction. The company’s operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
Contact
No. 108, Yuxin Road
8th Floor, Building A
Suzhou Industrial Park District
Suzhou215123
CHNT: +86 51262898861
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
315
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.40 | 19.00 | -0.21% |
| CAC 40 | 8,161.34 | 65.98 | -0.80% |
| DAX 40 | 24,141.72 | 13.73 | -0.06% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,413.56 | 43.45 | -0.42% |
| HKSE | 25,959.41 | 44.21 | 0.17% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,716.18 | 575.95 | 0.97% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,786.50 | 12.10 | -0.14% |
| SSE Composite Index | 4,079.90 | 13.35 | -0.33% |